– USA, CA – Coherus BioSciences, Inc. (Nasdaq: CHRS) today announced the appointment of board-certified oncologist and seasoned healthcare executive Dr. Lee Newcomer (M.D.), to its Board of Directors effective February 2, 2022.
“We are pleased to welcome Dr. Newcomer to the Coherus Board of Directors. Lee has dedicated his career to improving care for people with cancer by applying his expertise in clinical oncology, access and reimbursement. His unique understanding of the healthcare industry will help us accelerate our strategic evolution into a leading innovative immuno-oncology company,” said CEO, Denny Lanfear.
Mr. Lanfear added, “Market access strategy and execution are critically important to the upcoming launch of YUSIMRY into the $18 billion U.S. adalimumab market as well as our immuno-oncology strategy with toripalimab and PD-1 combination product candidates. Lee’s unique health care insights and expertise will play a significant role in refining our medical and commercial strategy for these products.”
The company also announced Dr. James Healy, a board member since 2014, has resigned from the Board of Directors.
About Dr. Lee N. Newcomer
Dr. Newcomer spent the majority of his career with UnitedHealthcare, where he most recently served as SVP, Oncology and Genetics, focusing on improving the affordability and quality of oncology care. He joined UnitedHealthcare in 1991 as CMO. Earlier, Dr. Newcomer served as Medical Director for CIGNA Health Care of Kansas City and was a practicing oncologist for nine years. Dr. Newcomer serves on the boards of directors of Cellworks Group and Myriad Genetics.
He received a B.S. degree in Biology from Nebraska Wesleyan University and an M.D. from the University of Nebraska-Omaha. Dr. Newcomer earned a Master’s Degree in Health and Health Care Administration and Management from the University of Wisconsin-Madison.
“With the upcoming launch of YUSIMRY, Coherus has the potential to deliver significant savings to patients and payers as the adalimumab market is made more efficient,” said Dr. Newcomer. “I am confident that the Company has the fundamental capabilities and product offerings necessary to achieve commercial success with both YUSIMRY and its novel immuno-oncology product candidates.”
About Coherus BioSciences
Coherus is a commercial-stage biopharmaceutical company building a leading immuno-oncology franchise funded with cash generated by its commercial biosimilar business. In 2021, Coherus in-licensed toripalimab, an anti-PD-1 antibody, in the United States and Canada. A biologics license application for toripalimab for the treatment of metastatic or recurrent nasopharyngeal carcinoma is currently under priority review by the FDA, with a target action date of April 2022. Toripalimab is also being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder.
Coherus markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The FDA is currently reviewing the biologics license application for CIMERLI, formerly CHS-201, a biosimilar of Lucentis, with a target action date of August 2022. Coherus is also developing CHS-305, a biosimilar to Avastin.
For more information: https://www.coherus.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.